Our Strategy

Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Our portfolio of investigational spleen tyrosine kinase (SYK) inhibitors are being developed to treat certain genetic subtypes of acute myeloid leukemia, one of the most difficult-to-treat blood cancers. We are also developing KB-0742, a selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) for the treatment of MYC-dependent solid tumors. In addition, we have multiple oncology discovery programs targeting dysregulated transcription factors.

Our Science

Targeting dysregulated transcription factors in cancer

Addressing the complexity of oncogenic TRNs requires a sophisticated and holistic approach to targeting cancer biology. TRNs encompass hundreds of proteins that function in a coordinated fashion to orchestrate specific gene expression programs that control development and function of healthy cells. Dysregulated TRNs resulting from aberrant transcription factor expression or activity are frequently responsible for reprogramming healthy cells into cancerous tumor cells. We apply computational biology to map the TRNs and identify the critical nodes and gene expression signatures that drive cancer. We believe that these critical nodes present attractive targets for therapeutic intervention using a biomarker-driven precision medicine strategy.

Product Engine

Our product engine includes four interconnected components, each of which is informed by our translational expertise, that enable efficient, hypothesis-driven clinical development of our product candidates:

map icon
screen icon
optimize icon
validate

Identify gene expression signature of selective TRN modulation

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

Refine pharmacological properties to yield attractive product development candidates

Hypothesis driven clinical trials to deliver proof of concept early in the development process

map icon

Identify gene expression signature of selective TRN modulation​

screen icon

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

optimize icon

Refine pharmacological properties to yield attractive development candidates

validate

Hypothesis driven clinical trials to deliver proof of concept early in the development process

Pipeline/Programs

We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline, including our lead product candidate, ENTO, as well as our discovery programs and our next anticipated milestones.

Target/Product
Candidate

Discovery

IND-Enabling Studies

Phase 1 Trial

Phase 2 Trial

Phase 3 Trial

Next Anticipated Milestone

SYK Inhibitor

  • 2H 2021: Initiate NPM1 mt AML registrational Phase 3 clinical trial
  • H2 2023: Topline data readout of Phase 3  registrational trial
  • 4Q 2021: Initiate FLT3 mt AML Phase 1/2 clinical trial
  • 2H 2022: Initial data readout of safety, PK/PD data
  • 1H 2022: Initiate NPM1 or FLT3 mt AML Phase 1/2 clinical trial
  • 1H 2023: Initial data readout of safety, PK/PD data

CDK9 Inhibitor

  • Q4 2021: Topline data readout of safety. PK and PD data from Phase 1/2 clinical trial dose escalation cohorts
  • 2022: Initial data readout of Phase 1/2 clinical trial expansion cohorts

Other

MYB, AR, IRF4, ASCL1, MYC

  • IND submission from one of these programs expected in 2H 2022 or 1H 2023

*We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.

Color Band

Careers

JOIN OUR TEAM

We are looking for innovative team members who share our passion for transformative science paired with unparalleled execution.

See our current list of openings below or submit your resume to careers@kronosbio.com.

woman in lab
Kronos Bio